A year ago, a man was walking down a sidewalk in the heart of San Francisco when he passed a woman with a baby in her arms.
He asked her, “Hey, do you want a free Lactate Shot?”
The woman smiled and told him she did.
But the Lactated Man had a different idea.
He grabbed the baby, threw him to the ground and started kicking her.
He told her, “[You’re] stupid.
You’re going to get a concussion.”
The baby’s mom screamed and told the guy, “I don’t care what you do, don’t do that to your baby!”
The guy laughed and said, “Just shut the fuck up.”
The mother called 911.
As the paramedics were pulling the infant from the woman, she told them, “Please, please, please help me.
I don’t want to die.”
That’s when the paramedics realized they had a lifesaving Lactator Shot in their arsenal.
In 2015, the California Department of Public Health spent $6 million to fund the first phase of the state’s Lactative Illness Treatment Program.
This program, known as the LITP, aims to prevent and treat Lactators through the delivery of Lactoid Therapy, or LTT, an injectable liquid used to treat LCT, a blood condition caused by a deficiency in certain Lactase genes.
LCT is a rare disease, affecting just one in every 3,000 babies born in the U.S. Each year, about 6,000 LCT patients are treated with the LTT.
But even with the massive investment in the LCT program, it’s still far from a cure.
“It’s the most expensive LCT treatment ever funded,” says Brian Kallman, a professor of pediatric neurology and neuroscience at the University of California, San Francisco.
In addition to the cost of the LST, the LMT can cost anywhere from $20,000 to $300,000.
If a LCT patient is hospitalized, the state typically pays about $4.50 per LCT administered.
The LMT costs roughly the same as the cost to treat the patient in a hospital.
That’s because it requires the delivery and subsequent transport of the baby and patient, as well as the hospitalization of the infant.
The baby has to be hospitalized and then transferred to the hospital, where the LTC is administered, which can take anywhere from three hours to three days.
“You are literally moving your entire family out of the hospital and into the NICU,” says David Wojciechowski, director of the Institute for Neuroethics at Emory University.
“That’s a huge, huge expense for families who are already strapped for cash.”
In 2017, the hospitalized LCT group of babies who received the LDT had an average life expectancy of two months, according to a study by the University at Buffalo.
The average life span of the group who received LCT in the NICUs was about eight months.
That study also found that about 60 percent of LCT recipients who received injections of the medication survived.
While LCT has the potential to treat patients with the most severe forms of Lct, the risks of infection are high.
In the first six months of the program, the New York State Department of Health reported a 4.5 percent increase in infections among the Lct recipients.
But as the program’s costs grow, it has become increasingly difficult to treat infections that are unrelated to LCT.
“The LCT infusion of babies is a lifesaver,” Kallmann says.
“If you think about it, LCT therapy is a life-saving treatment.
You have a baby with no symptoms and the next thing you know, the baby’s in ICU.”
As the program expanded, however, the costs were also growing.
In 2018, the State of California reported that it would spend $6.2 million to support the LACTATE program, including $1.8 million for the LUTS.
This cost includes $1 million for an initial study of LACTAT, which was set up to identify the best LCT delivery method for LCTs in babies and toddlers, and $800,000 for additional studies of LTT in babies.
In 2017 alone, the program spent $1,543,000 on the LNT.
“We are not spending enough money on LCT,” Kupelnick says.
As a result, LDT has become the most popular LCT injection in the country.
Lactatrix, a company that makes the injectable LCT LCT (which is also known as a LIT or LCTT) is still making more than a million doses a year.
As of March 31, 2018, there were more than 1.2 billion LCT injections being made worldwide, with more than one